SCHEMBL24815337

SCHEMBL24815337

COC(=O)c1ccc2c(c1)n(C)c(=O)n2C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPD P32754 2/20 0.52
SMN1; SMN2 Q16637 5/20 0.48
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
BRD4 O60885 2/20 0.48
BRPF1 P55201 2/20 0.48
HSD17B10 Q99714 2/20 0.48
GAA P10253 1/20 0.45
GLA P06280 1/20 0.44
SLC22A12 Q96S37 1/20 0.43
CASP3 P42574 1/20 0.43
POLB P06746 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ATM Q13315 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30048876 1.00 HPD (0.52) HPDSMN1; SMN2KDM4EALDH1A1BRD4
SCHEMBL7539164 0.85 SMN1; SMN2 (0.65) SMN1; SMN2KDM4EALDH1A1BRD4BRPF1
SCHEMBL24815336 0.84 SLC22A12 (0.57) HPDSMN1; SMN2KDM4EALDH1A1BRD4
SCHEMBL24812336 0.84 HPD (0.55) HPDSMN1; SMN2KDM4EALDH1A1BRD4
SCHEMBL30049030 0.84 SLC22A12 (0.57) HPDSMN1; SMN2KDM4EALDH1A1BRD4
SCHEMBL25139613 0.82 HPD (0.54) HPDSMN1; SMN2KDM4EALDH1A1BRD4
SCHEMBL6054648 0.82 HPD (0.46) HPDSMN1; SMN2KDM4EALDH1A1BRD4
SCHEMBL6054650 0.81 HPD (0.48) HPDSMN1; SMN2KDM4EALDH1A1BRD4
SCHEMBL25139664 0.80 HPD (0.52) HPDSMN1; SMN2KDM4EALDH1A1BRD4
SCHEMBL27446319 0.78 HPD (0.62) HPDSMN1; SMN2KDM4EALDH1A1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117561058-A CDK2 inhibitors and methods of use thereof 塞迪拉治疗股份有限公司 2024-02-13 CN disclosed
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. 2023-04-20 US disclosed
WO-2022272106-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121337-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK2AP2 HPD 3886/4885SMN1; SMN2 1898/4885KDM4E 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.